Among them, IL-18 was nominally associated with the risk of six types of cancer, including bladder cancer (OR=0.86, 95% CI: 0.79-0.93, P=3.30×10-4), breast cancer (OR=1.05, 95% CI: 1.01-1.09, P=0.027), chronic lymphoid leukemia (CLL) (OR=1.39, 95% CI: 1.29-1.71, P=0.002), kidney cancer (OR=0.87, 95% CI: 0.77-0.99, P=0.028), multiple myeloma (OR=0.76, 95% CI: 0.63-0.90, P=0.002), non-Hodgkin lymphoma (OR=0.84, 95% CI: 0.74-0.96, P=0.008). Here, IL18 is linked to plasma cell myeloma.